Pharmacovigilance in Kala-azar patients with severe thrombocytopenia caused by soduim antimony gluconate & miltefosine

Indian Journal of Medical Research

Volumn 126, Issue 1, 2007, Pages 73-75

  Thakur, C P ^a,b   Kumar, A ^a   Mitra, G ^a   Thakur, S ^a   Thakur, M ^a  

^a Balaji Utthan Sansthan   (India)

^b NONE   (India)

Author keywords

Haemorrhages; Miltefosine; Pharamacovigilance; Soduim antimony gluconate; Thrombocytopenia

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIMONY GLUCONATE; DEXAMETHASONE; MILTEFOSINE; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ADOLESCENT; ADULT; ARTICLE; ASPIRATION; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; LEISHMANIA DONOVANI; LEISHMANIASIS; MALE; MORNING DOSAGE; RELAPSE; SPLEEN; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; THROMBOCYTOPENIA;

EID: 35548965038     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Sen Gupta PC. Chemotherapy of leishmanial diseases: a resume of recent researches. Indian Med Gaz 1953; 88: 20-35.
2. Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK. Rationalization of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J 1988; 296: 1557-61.
3. Harrison WN, Bradberry SM, Vale JA. Sodium stibogluconate: UKPID MONOGRAPH, National Poisons Information Services, (Birmingham Centre). West Midlands. Midland Poisons Unit City Hospital NHS Trust, Dudley Road Birmingham B 18 7QH,UK; 1998.
4. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang F, Fischer C, et al. Miltefosine, an oral agent for the treatment of visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
5. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004; 38: 217-21.
6. Drugs causing thrombocytopenia or low platelet count http://medicineworld.org/physicians/hematology/ thrombocytopenia.html accessed on Apirl 5, 2007.
7. Chunge CN, Gachihi G, Chulay JD, Spencer HC. Complications of kala-azar and its treatment in Kenya. East Afr Med J 1984; 61: 120-7.
8. De Wolff FA. Antimony and health. BMJ 1995; 310: 1216-7.
9. Guidance for Industry E2E Pharmacovigilance Planning U.S Department of Health and Human Services, Food and Drug Administration, April 2005 p. 1-17.
10. Human Medicines- pharmacovigilance Working Party (PhVWP), European Medicines Agency, Available at www.emea.europa.eu, accessed on May 5, 2006.
11. Guide to ADR Reporting/ADR Form. The National Coordinator, National Pharmacovigilance Centre (NPC), National Agency for Food and Drug Administration and Control, plot 2032 Olusegun Obansanjo WAy, Wuse Zone 7, Abuja PMB 5032 Wuse Abuja Website: http://www.nafdacnigeria.org/ pharmacovigilance.html.
12. RamDoss A. Reply to half hour discussion on ban on globally discarded drugs. Rajya Sabha of India on 17 February 2006. Lok Sabha Secretariat. http://164.100.24.167/rsdebat/synopsis/207/s18052005.html.